Login Register Cart 0
Generic placeholder image

Current Diabetes Reviews

Editor-in-Chief

ISSN (Print): 1573-3998
ISSN (Online): 1875-6417

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Analysis of Robustness of the Landmark Cardiovascular Outcome Trials of Antidiabetic Drugs - A Systematic Review

Author(s): Debdipta Bose and Mahanjit Konwar*

Volume 18, Issue 6, 2022

Published on: 17 January, 2022

Article ID: e140921196472 Pages: 10

DOI: 10.2174/1573399817666210914114511

Price: $65

conference banner
Abstract

Background: It is essential for randomized controlled trials (RCTs) to report results in a comprehensive manner. Hence, it is necessary to assess the robustness of the trials with statistically significant and as well as non-significant results. Robustness can be evaluated using fragility index (FI), while reverse fragility index (RFI) can be used for trials with statistically significant as well as non-significant results. The primary aim of this study was to calculate FI and RFI for cardiovascular outcome trials (CVOT).

Materials and Methods: PubMed/MEDLINE was searched to identify all RCTs of antidiabetic drugs where the primary objective was to evaluate the cardiovascular outcomes. We recorded the trial characteristics of each CVOT trial. The FI, RFI, fragility quotient (FQ), and reverse fragility quotient (RFQ) were calculated to evaluate the robustness of the trials. Spearman rank correlation test was used for correlation.

Findings: A total of 889 studies were identified and 24 RCTs were included. Among the 24 trials, 12 (50%) trials achieved statistical significance. The median FI and RFI were 29 (4-12) and 22.5 (1-37) for trials with statistically significant and non-significant results. The median FQ and RFQ were 0.0075 (0.002-0.013) and 0.0003 (0.0001-0.004) for trials with statistically significant and non-significant results. The hazard ratio, p-value, and NNT-B had a strong negative relationship with FI.

Interpretation: Our study showed that half of the trials showing the superiority of cardioprotective benefits have favourable FI. The trials that failed to show superiority also have a reasonable RFI indicating the robustness of these trials. However, the results of the trials where patients lost to follow- up exceed the FI of that trial demands caution during interpretation.

Keywords: Robustness, lost to follow-up, fragility quotient, p-value, reverse fragility index (RFI), cardioprotective benefits.

[1]
Zelniker TA, Braunwald E. Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review. J Am Coll Cardiol 2018; 72(15): 1845-55.
[http://dx.doi.org/10.1016/j.jacc.2018.06.040] [PMID: 30075873]
[2]
Pocock SJ, McMurray JJV, Collier TJ. Making sense of statistics in clinical trial reports: Part 1 of a 4-part series on statistics for clinical trials. J Am Coll Cardiol 2015; 66(22): 2536-49.
[http://dx.doi.org/10.1016/j.jacc.2015.10.014] [PMID: 26653629]
[3]
Scales CD Jr, Norris RD, Preminger GM, Vieweg J, Peterson BL, Dahm P. Evaluating the evidence: Statistical methods in randomized controlled trials in the urological literature. J Urol 2008; 180(4): 1463-7.
[http://dx.doi.org/10.1016/j.juro.2008.06.026] [PMID: 18710745]
[4]
Walsh M, Srinathan SK, McAuley DF, et al. The statistical significance of randomized controlled trial results is frequently fragile: A case for a Fragility Index. J Clin Epidemiol 2014; 67(6): 622-8.
[http://dx.doi.org/10.1016/j.jclinepi.2013.10.019] [PMID: 24508144]
[5]
Tignanelli CJ, Napolitano LM. The fragility index in randomized clinical trials as a means of optimizing patient care. JAMA Surg 2019; 154(1): 74-9.
[http://dx.doi.org/10.1001/jamasurg.2018.4318] [PMID: 30422256]
[6]
Khan MS, Fonarow GC, Friede T, et al. Application of the reverse fragility index to statistically nonsignificant randomized clinical trial results. JAMA Netw Open 2020; 3(8): e2012469.
[http://dx.doi.org/10.1001/jamanetworkopen.2020.12469] [PMID: 32756927]
[7]
Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375(4): 323-34.
[http://dx.doi.org/10.1056/NEJMoa1515920] [PMID: 27299675]
[8]
Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020; 383(15): 1413-24.
[http://dx.doi.org/10.1056/NEJMoa2022190] [PMID: 32865377]
[9]
Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377(7): 644-57.
[http://dx.doi.org/10.1056/NEJMoa1611925] [PMID: 28605608]
[10]
McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381(21): 1995-2008.
[http://dx.doi.org/10.1056/NEJMoa1911303] [PMID: 31535829]
[11]
Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380(4): 347-57.
[http://dx.doi.org/10.1056/NEJMoa1812389] [PMID: 30415602]
[12]
Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med 2021; 384(2): 129-39.
[http://dx.doi.org/10.1056/NEJMoa2030186] [PMID: 33200891]
[13]
Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 2021; 384(2): 117-28.
[http://dx.doi.org/10.1056/NEJMoa2030183] [PMID: 33200892]
[14]
Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 2020; 383(15): 1425-35.
[http://dx.doi.org/10.1056/NEJMoa2004967] [PMID: 32966714]
[15]
Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017; 377(13): 1228-39.
[http://dx.doi.org/10.1056/NEJMoa1612917] [PMID: 28910237]
[16]
Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015; 373(23): 2247-57.
[http://dx.doi.org/10.1056/NEJMoa1509225] [PMID: 26630143]
[17]
Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): A double-blind, randomised placebo-controlled trial. Lancet 2018; 392(10157): 1519-29.
[http://dx.doi.org/10.1016/S0140-6736(18)32261-X] [PMID: 30291013]
[18]
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375(4): 311-22.
[http://dx.doi.org/10.1056/NEJMoa1603827] [PMID: 27295427]
[19]
Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2019; 381(9): 841-51.
[http://dx.doi.org/10.1056/NEJMoa1901118] [PMID: 31185157]
[20]
Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial. Lancet 2019; 394(10193): 121-30.
[http://dx.doi.org/10.1016/S0140-6736(19)31149-3] [PMID: 31189511]
[21]
Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375(19): 1834-44.
[http://dx.doi.org/10.1056/NEJMoa1607141] [PMID: 27633186]
[22]
Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptinvsplacebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: The carmelina randomized clinical trial. JAMA 2019; 321(1): 69-79.
[http://dx.doi.org/10.1001/jama.2018.18269] [PMID: 30418475]
[23]
Rosenstock J, Kahn SE, Johansen OE, et al. Effect of linagliptinvsglimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: The carolina randomized clinical trial. JAMA 2019; 322(12): 1155-66.
[http://dx.doi.org/10.1001/jama.2019.13772] [PMID: 31536101]
[24]
White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369(14): 1327-35.
[http://dx.doi.org/10.1056/NEJMoa1305889] [PMID: 23992602]
[25]
Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369(14): 1317-26.
[http://dx.doi.org/10.1056/NEJMoa1307684] [PMID: 23992601]
[26]
Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373(3): 232-42.
[http://dx.doi.org/10.1056/NEJMoa1501352] [PMID: 26052984]
[27]
Gantz I, Chen M, Suryawanshi S, et al. A randomized, placebo- controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 2017; 16(1): 112.
[http://dx.doi.org/10.1186/s12933-017-0593-8] [PMID: 28893244]
[28]
Hu K, Xu W, Williams Z. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 2016; 375(7): 703-4.
[PMID: 27532848]
[29]
Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med 2017; 377(8): 723-32.
[http://dx.doi.org/10.1056/NEJMoa1615692] [PMID: 28605603]
[30]
Holman RR, Coleman RL, Chan JCN, et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): A randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2017; 5(11): 877-86.
[http://dx.doi.org/10.1016/S2213-8587(17)30309-1] [PMID: 28917545]
[31]
Khan MS, Ochani RK, Shaikh A, et al. Fragility index in cardiovascular randomized controlled trials. Circ Cardiovasc Qual Outcomes 2019; 12(12): e005755.
[http://dx.doi.org/10.1161/CIRCOUTCOMES.119.005755] [PMID: 31822121]
[32]
Matics TJ, Khan N, Jani P, Kane JM. The fragility index in a cohort of pediatric randomized controlled trials. J Clin Med 2017; 6(8): 79.
[http://dx.doi.org/10.3390/jcm6080079] [PMID: 28805717]
[33]
Kennedy-Shaffer L. When the Alpha is the Omega: P-Values, “Substantial Evidence,” and the 0.05 Standard at FDA. Food Drug Law J 2017; 72(4): 595-635.
[PMID: 30294197]
[34]
Carter RE, McKie PM, Storlie CB. The fragility index: A p-value in sheep’s clothing? Eur Heart J 2017; 38(5): 346-8.
[PMID: 28417139]

Rights & Permissions Print Cite
Article Metrics
17
1
© 2024 Bentham Science Publishers | Privacy Policy